SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
The Market For Follow-On Biologics: How Will It Evolve?
6 references·3 citing·32 second hop
The Market For Follow-On Biologics: How Will It Evolve? (2006)The Market For Follow-On Biologics: How W…The cost of biopharmaceutical R&D: is biotech different? (2007)The cost of biopharmaceutical…Patents and New Product Development in the Pharmaceutical and Biotechnology Industries (2006)Patents and New Product Devel…Generic Competition in the US Pharmaceutical Industry (2006)Generic Competition in the US…Are the Economics of Pharmaceutical Research and Development Changing? (2004)Are the Economics of Pharmace…The price of innovation: new estimates of drug development costs (2003)The price of innovation: new …Overview of the Hatch-Waxman Act and its impact on the drug development process. (1999)Overview of the Hatch-Waxman …Determinants of Market Exclusivity for Prescription Drugs in the United States (2017)Determinants of Market Exclus…The biotechnology sector and US gene patents: Legal challenges to intellectual property rights and the impact on basic research and development (2012)The biotechnology sector and …IP Issues of Therapeutic Antibodies (2012)IP Issues of Therapeutic Anti…Principles of Corporate Finance. (1981)Cost of innovation in the pharmaceutical industry (1991)Deconstructing the Drug Development Process: The New Face of Innovation (2010)The cost of drug development: A systematic review (2011)Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval (2017)Returns on Research and Development for 1990s New Drug Introductions (2002)Innovation Policy and the Economy (2007)Physical scientists research biomedicine: a call for caution. (2015)Patent cliff and strategic switch: exploring strategic design possibilities in the pharmaceutical industry (2016)Standing on the Shoulders of Giants: Cumulative Research and the Patent Law (1991)Can Patents Deter Innovation? The Anticommons in Biomedical Research (1998)The Tragedy of the Anticommons: Property in the Transition from Marx to Markets (1998)Industrial Market Structure and Economic Performance. (1971)Appropriating the Returns from Industrial Research and Development (1987)Macro trends in pharmaceutical innovation (2005)Follow-on biologics: data exclusivity and the balance between innovation and competition (2008)Nonlinear Effects of Taxation on Growth (2016)Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act (1992)What do we know about entry? (1995)Generic Entry and the Pricing of Pharmaceuticals (1997)Pharmaceutical pricing policies in a global market (2008)Balancing Innovation and Access: Patent Challenges Tip the Scales (2009)Generic Drug Industry Dynamics (2005)Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009 (2010)The High Cost of Prescription Drugs in the United States (2016)Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists (2023)Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry (2011)Quantifying the economic impact of government and charity funding of medical research on private research and development funding in the United Kingdom (2016)Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry (2016)Can the pharmaceutical industry reduce attrition rates? (2004)Clinical development success rates for investigational drugs (2014)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)
this work references cited by second hop

References

  • 2003The price of innovation: new estimates of drug development costs4,264 cited
  • 2007The cost of biopharmaceutical R&D: is biotech different?517 cited
  • 2006Generic Competition in the US Pharmaceutical Industry145 cited
  • 1999Overview of the Hatch-Waxman Act and its impact on the drug development process.131 cited
  • 2004Are the Economics of Pharmaceutical Research and Development Changing?88 cited
  • 2006Patents and New Product Development in the Pharmaceutical and Biotechnology Industries45 cited

Cited by

  • 2017Determinants of Market Exclusivity for Prescription Drugs in the United States71 cited
  • 2012IP Issues of Therapeutic Antibodies9 cited
  • 2012The biotechnology sector and US gene patents: Legal challenges to intellectual property rights and the impact on basic research and development8 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work